Aclaris Therapeutics (ACRS) Reports Q4 Loss of $0.28/Share

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 EPS of ($0.28), versus ($1.76) reported last year.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Cerebras Q1 EPS miss sends shares down 9% after-hours
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal